BD-011

BD-011 is an autologous T-cell receptor engineered T-cell (TCR-T) therapy developed by Shenzhen BinDe Biological Technology (BinDeBio). The therapy involves the genetic modification of a patient's own T cells using a lentiviral vector to express a high-affinity T-cell receptor (TCR) specific for the New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen. This TCR recognizes NY-ESO-1 peptides presented by the HLA-A*02:01 major histocompatibility complex. NY-ESO-1 is a cancer-testis antigen that is highly expressed in various malignancies but has restricted expression in normal tissues, making it a precise target for immunotherapy. Once re-infused into the patient, these engineered T cells are designed to selectively identify and eliminate NY-ESO-1-positive tumor cells. BD-011 is currently being investigated in Phase 1 clinical trials for the treatment of advanced solid tumors, including non-small cell lung cancer, esophageal cancer, and melanoma.

Other names

anti-NY-ESO-1 TCR-Tanti-NY-ESO1 TCR-Tanti-NY-ESO 1 TCR-TNY-ESO-1-TCR-T cell therapyNY-ESO1-TCR-T cell therapyNY-ESO 1-TCR-T cell therapyNY-ESO-1-specific TCR-T cellsNY-ESO1-specific TCR-T cellsNY-ESO 1-specific TCR-T cells